|

Clinicopathological Value of p16 Expression in Colorectal Carcinoma

RECRUITINGSponsored by Sohag University
Actively Recruiting
SponsorSohag University
Started2025-05-01
Est. completion2026-03-21
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07047482

Summary

Evaluation of the immunohistochemical expression of p16 in colorectal carcinoma and correlate its expression to different clinical and pathological parameters as patients' ages, sexes, tumor location, histopathological phenotype, status of nodal involvement, perineural and lymphovascular invasion.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

1. Specimens from patients with colorectal cancer.
2. Tissue blocks with sufficient material.
3. Specimens with sufficient clinical data.

Exclusion Criteria:

1. Tissue blocks with insufficient, destroyed or necrotic material.
2. Specimens with insufficient clinical data.

Conditions2

CancerColorectal Carcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.